Advertisement

Index by Author

December 2000; 49 (12)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Ader, M

    • Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. Diabetes December 2000 49:2087-2093; doi:10.2337/diabetes.49.12.2087

  2. Agius, L

    • Subcellular localization, mobility, and kinetic activity of glucokinase in glucose-responsive insulin-secreting cells. Diabetes December 2000 49:2048-2055; doi:10.2337/diabetes.49.12.2048

  3. Aiston, S

    • Subcellular localization, mobility, and kinetic activity of glucokinase in glucose-responsive insulin-secreting cells. Diabetes December 2000 49:2048-2055; doi:10.2337/diabetes.49.12.2048

  4. Aitman, T J

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  5. Akerblom, H K

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  6. Andrews, K M

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  7. Andrikopoulos, S

    • beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes December 2000 49:2056-2062; doi:10.2337/diabetes.49.12.2056

  8. Antunes, C M

    • Differential patterns of glucose-induced electrical activity and intracellular calcium responses in single mouse and rat pancreatic islets. Diabetes December 2000 49:2028-2038; doi:10.2337/diabetes.49.12.2028

  9. Araki, S

    • APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes December 2000 49:2190-2195; doi:10.2337/diabetes.49.12.2190

  10. Arisawa, K

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

B

  1. Bakopanos, E

    • Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level. Diabetes December 2000 49:2108-2115; doi:10.2337/diabetes.49.12.2108

  2. Bartocci, L

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  3. Begum, N

    • Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes December 2000 49:2178-2189; doi:10.2337/diabetes.49.12.2178

  4. Bennett, P H

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  5. Bergman, R N

    • Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. Diabetes December 2000 49:2087-2093; doi:10.2337/diabetes.49.12.2087
    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  6. Blaak, E E

    • Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes December 2000 49:2102-2107; doi:10.2337/diabetes.49.12.2102

  7. Bliss, C R

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  8. Bogardus, C

    • A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes December 2000 49:2094-2101; doi:10.2337/diabetes.49.12.2094

  9. Bolli, G B

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  10. Bougnères, P

    • A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes December 2000 49:2196-2200; doi:10.2337/diabetes.49.12.2196

  11. Bouillon, R

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

  12. Bowen, S

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  13. Brady, M J

    • Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes December 2000 49:1967-1977; doi:10.2337/diabetes.49.12.1967

  14. Brunetti, P

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

C

  1. Caprio, S

    • Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes December 2000 49:2149-2153; doi:10.2337/diabetes.49.12.2149

  2. Carling, D

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  3. Caumo, A

    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  4. Ceriello, A

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

  5. Chandramouli, V

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063
    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  6. Chapman, H D

    • Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes December 2000 49:2007-2011; doi:10.2337/diabetes.49.12.2007

  7. Chin, J E

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  8. Chipkin, S

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  9. Cobelli, C

    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  10. Collison, M

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  11. Connell, J M

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  12. Cooksey, R C

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  13. Cordoni, C

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  14. Corkey, B E

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  15. Costa, E

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  16. Crook, E D

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  17. Cupples, L A

    • Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes December 2000 49:2201-2207; doi:10.2337/diabetes.49.12.2201

  18. Curtis, S

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

D

  1. Dabelea, D

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  2. Damante, G

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

  3. Daniels, M C

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  4. Davis, D A

    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  5. Dea, M K

    • Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. Diabetes December 2000 49:2087-2093; doi:10.2337/diabetes.49.12.2087
    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  6. Dekker, K A

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  7. Dillon, J S

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  8. Di Vincenzo, A

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  9. Dominiczak, A F

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  10. Dominiczak, M H

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  11. Dubins, J S

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  12. Dufour, S

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

E

  1. Enoksson, S

    • Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes December 2000 49:2149-2153; doi:10.2337/diabetes.49.12.2149

F

  1. Fanelli, C

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  2. Fryer, L G

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  3. Fujihira, K

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

G

  1. Gabir, M M

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  2. Glazier, A M

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  3. Gombos, Z

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  4. Gould, G W

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  5. Graham, D

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

  6. Gysemans, C A

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

H

  1. Habener, J F

    • Hedgehog signaling regulation of insulin production by pancreatic beta-cells. Diabetes December 2000 49:2039-2047; doi:10.2337/diabetes.49.12.2039

  2. Hajduch, E

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  3. Hamilton-Wessler, M

    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  4. Hanafusa, T

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  5. Hanna, L

    • APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes December 2000 49:2190-2195; doi:10.2337/diabetes.49.12.2190

  6. Hanson, R L

    • A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes December 2000 49:2094-2101; doi:10.2337/diabetes.49.12.2094
    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  7. Hardie, D G

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  8. Hebert, L F, Jr

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  9. Hering, B J

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  10. Hevener, A L

    • Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat. Diabetes December 2000 49:2154-2159; doi:10.2337/diabetes.49.12.2154

  11. Hoffman, R T

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  12. Hulin, B

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  13. Hundal, H S

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  14. Hundal, R S

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

I

  1. Igarashi, K

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  2. Ilonen, J

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  3. Imagawa, A

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  4. Imperatore, G

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  5. Inagaki, T

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  6. Inzucchi, S E

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

J

  1. Jaffa, A A

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

  2. Jenkins, A J

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

  3. Ji, L

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  4. Johnson, E A

    • Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes December 2000 49:2007-2011; doi:10.2337/diabetes.49.12.2007

  5. Joyce, K C

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

K

  1. Kadowaki, T

    • beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes December 2000 49:2056-2062; doi:10.2337/diabetes.49.12.2056

  2. Kahn, C R

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

  3. Kahn, S E

    • beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes December 2000 49:2056-2062; doi:10.2337/diabetes.49.12.2056

  4. Kasuga, M

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  5. Kending, C

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  6. Kim, S P

    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  7. Klein, R L

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

  8. Klupa, T

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  9. Knip, M

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  10. Knowler, W C

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  11. Krolewski, A S

    • APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes December 2000 49:2190-2195; doi:10.2337/diabetes.49.12.2190
    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  12. Krssak, M

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

  13. Kulkarni, R N

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

  14. Kuznetsov, A

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

L

  1. Laine, A P

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  2. Landau, B R

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063
    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  3. Langefeld, C D

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  4. Laurent, D

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

  5. Laureys, J M

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

  6. Le Bihan, C

    • A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes December 2000 49:2196-2200; doi:10.2337/diabetes.49.12.2196

  7. Lebon, V

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

  8. Lee, J H

    • Hedgehog signaling regulation of insulin production by pancreatic beta-cells. Diabetes December 2000 49:2039-2047; doi:10.2337/diabetes.49.12.2039

  9. Lepore, M

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  10. Le Stunff, C

    • A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes December 2000 49:2196-2200; doi:10.2337/diabetes.49.12.2196

  11. Levy, C B

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  12. Li, M

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  13. Lindsay, R S

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  14. Lu, B

    • Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes December 2000 49:2007-2011; doi:10.2337/diabetes.49.12.2007

  15. Lyons, T J

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

M

  1. Maeda, S

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  2. Ma, L

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  3. Malecki, M T

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  4. Mathieu, C

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

  5. Matsuzawa, Y

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  6. Mauvais-Jarvis, F

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

  7. Mayfield, R K

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

  8. McClain, D A

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  9. McPherson, R K

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  10. Meigs, J B

    • Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes December 2000 49:2201-2207; doi:10.2337/diabetes.49.12.2201

  11. Mercuri, F

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

  12. Michael, M D

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

  13. Mihkalsky, D

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

  14. Mittelman, S D

    • Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. Diabetes December 2000 49:2087-2093; doi:10.2337/diabetes.49.12.2087
    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  15. Miyagawa, J

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  16. Moczulski, D K

    • APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes December 2000 49:2190-2195; doi:10.2337/diabetes.49.12.2190

  17. Moriwaki, M

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  18. Moriyama, H

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  19. Morocutti, A

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

  20. Moro, M

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

  21. Morton, J J

    • Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes December 2000 49:2222-2226; doi:10.2337/diabetes.49.12.2222

N

  1. Nagata, M

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  2. Nakajima, H

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  3. Nakayama, M

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  4. Namba, M

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  5. Nammo, T

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  6. Nejentsev, S

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  7. Newgard, C B

    • Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes December 2000 49:1967-1977; doi:10.2337/diabetes.49.12.1967

  8. Nielsen, M F

    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  9. Nyholm, B

    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

O

  1. O'Doherty, R M

    • Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes December 2000 49:1967-1977; doi:10.2337/diabetes.49.12.1967

  2. Okumura, K

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  3. Olefsky, J

    • Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat. Diabetes December 2000 49:2154-2159; doi:10.2337/diabetes.49.12.2154

P

  1. Pampanelli, S

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  2. Parker, J C

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  3. Patel, N

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  4. Perry, D A

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  5. Perry, P V

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  6. Petersen, K F

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

  7. Pettitt, D J

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

  8. Pezzolesi, M

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  9. Philipson, L H

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  10. Phillips, K D

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

  11. Porcellati, F

    • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes December 2000 49:2142-2148; doi:10.2337/diabetes.49.12.2142

  12. Post, C M

    • Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes December 2000 49:2007-2011; doi:10.2337/diabetes.49.12.2007

  13. Pratley, R E

    • A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes December 2000 49:2094-2101; doi:10.2337/diabetes.49.12.2094

  14. Prentki, M

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

Q

  1. Quagliaro, L

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

R

  1. Ragolia, L

    • Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes December 2000 49:2178-2189; doi:10.2337/diabetes.49.12.2178

  2. Rastalsky, N

    • Hedgehog signaling regulation of insulin production by pancreatic beta-cells. Diabetes December 2000 49:2039-2047; doi:10.2337/diabetes.49.12.2039

  3. Reichart, D

    • Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat. Diabetes December 2000 49:2154-2159; doi:10.2337/diabetes.49.12.2154

  4. Rencurel, F

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  5. Rich, S S

    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  6. Rife, F

    • Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes December 2000 49:2149-2153; doi:10.2337/diabetes.49.12.2149

  7. Rizza, R A

    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  8. Rosário, L M

    • Differential patterns of glucose-induced electrical activity and intracellular calcium responses in single mouse and rat pancreatic islets. Diabetes December 2000 49:2028-2038; doi:10.2337/diabetes.49.12.2028

  9. Rothman, P B

    • Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes December 2000 49:2007-2011; doi:10.2337/diabetes.49.12.2007

  10. Roumain, J

    • Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes December 2000 49:2208-2211; doi:10.2337/diabetes.49.12.2208

S

  1. Salgado, A P

    • Differential patterns of glucose-induced electrical activity and intracellular calcium responses in single mouse and rat pancreatic islets. Diabetes December 2000 49:2028-2038; doi:10.2337/diabetes.49.12.2028

  2. Saltiel, A R

    • Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes December 2000 49:1967-1977; doi:10.2337/diabetes.49.12.1967

  3. Salt, I P

    • Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes December 2000 49:1978-1985; doi:10.2337/diabetes.49.12.1978

  4. Sandu, O A

    • Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes December 2000 49:2178-2189; doi:10.2337/diabetes.49.12.2178

  5. Santos, R M

    • Differential patterns of glucose-induced electrical activity and intracellular calcium responses in single mouse and rat pancreatic islets. Diabetes December 2000 49:2028-2038; doi:10.2337/diabetes.49.12.2028

  6. Saris, W H

    • Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes December 2000 49:2102-2107; doi:10.2337/diabetes.49.12.2102

  7. Sasada, R

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  8. Schmitz, O

    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  9. Schork, N J

    • A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes December 2000 49:2196-2200; doi:10.2337/diabetes.49.12.2196

  10. Schuit, F C

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  11. Schultz, V

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  12. Schumann, W C

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063
    • Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes December 2000 49:2135-2141; doi:10.2337/diabetes.49.12.2135

  13. Scott, L J

    • APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes December 2000 49:2190-2195; doi:10.2337/diabetes.49.12.2190

  14. Serreze, D V

    • Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes December 2000 49:2007-2011; doi:10.2337/diabetes.49.12.2007

  15. Sherwin, R S

    • Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes December 2000 49:2149-2153; doi:10.2337/diabetes.49.12.2149

  16. Shulman, G I

    • Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes December 2000 49:2063-2069; doi:10.2337/diabetes.49.12.2063

  17. Silva, J E

    • Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level. Diabetes December 2000 49:2108-2115; doi:10.2337/diabetes.49.12.2108

  18. Simell, O

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  19. Stubbs, M

    • Subcellular localization, mobility, and kinetic activity of glucokinase in glucose-responsive insulin-secreting cells. Diabetes December 2000 49:2048-2055; doi:10.2337/diabetes.49.12.2048

  20. Sugie, Y

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  21. Sunehag, A L

    • Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. Diabetes December 2000 49:2087-2093; doi:10.2337/diabetes.49.12.2087

T

  1. Tachikawa, K

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

  2. Talbot, M

    • Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes December 2000 49:2149-2153; doi:10.2337/diabetes.49.12.2149

  3. Tamarina, N

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  4. Tamborlane, W V

    • Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes December 2000 49:2149-2153; doi:10.2337/diabetes.49.12.2149

  5. Tang, J

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  6. Tataranni, P A

    • A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes December 2000 49:2094-2101; doi:10.2337/diabetes.49.12.2094

  7. Terauchi, Y

    • beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes December 2000 49:2056-2062; doi:10.2337/diabetes.49.12.2056

  8. Thomas, M K

    • Hedgehog signaling regulation of insulin production by pancreatic beta-cells. Diabetes December 2000 49:2039-2047; doi:10.2337/diabetes.49.12.2039

  9. Tochino, Y

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  10. Treadway, J L

    • Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes December 2000 49:2079-2086; doi:10.2337/diabetes.49.12.2079

V

  1. Vaarala, O

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  2. Valckx, D

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

  3. van Aggel-Leijssen, D P

    • Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes December 2000 49:2102-2107; doi:10.2337/diabetes.49.12.2102

  4. van Baak, M A

    • Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes December 2000 49:2102-2107; doi:10.2337/diabetes.49.12.2102

  5. Van Citters, G W

    • Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. Diabetes December 2000 49:2087-2093; doi:10.2337/diabetes.49.12.2087
    • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes December 2000 49:2116-2125; doi:10.2337/diabetes.49.12.2116

  6. Veerababu, G

    • Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes December 2000 49:2070-2078; doi:10.2337/diabetes.49.12.2070

  7. Veijola, R

    • Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B. Diabetes December 2000 49:2217-2221; doi:10.2337/diabetes.49.12.2217

  8. Velarde, V

    • Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes December 2000 49:2160-2169; doi:10.2337/diabetes.49.12.2160

  9. Verchere, C B

    • beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes December 2000 49:2056-2062; doi:10.2337/diabetes.49.12.2056

  10. Viberti, G C

    • Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes December 2000 49:2170-2177; doi:10.2337/diabetes.49.12.2170

  11. Virkamaki, A

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

  12. Voilley, N

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

W

  1. Waer, M

    • Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes December 2000 49:1992-1997; doi:10.2337/diabetes.49.12.1992

  2. Wagenmakers, A J

    • Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes December 2000 49:2102-2107; doi:10.2337/diabetes.49.12.2102

  3. Waguri, M

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  4. Wang, Y

    • Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes December 2000 49:1986-1991; doi:10.2337/diabetes.49.12.1986

  5. Warram, J H

    • APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes December 2000 49:2190-2195; doi:10.2337/diabetes.49.12.2190
    • Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes December 2000 49:2212-2216; doi:10.2337/diabetes.49.12.2212

  6. Waxman, D J

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  7. Weyer, C

    • A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes December 2000 49:2094-2101; doi:10.2337/diabetes.49.12.2094

  8. Wilson, P W

    • Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes December 2000 49:2201-2207; doi:10.2337/diabetes.49.12.2201

  9. Winnay, J N

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

Y

  1. Yagita, H

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  2. Yamagata, K

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  3. Yamamoto, K

    • Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes December 2000 49:2021-2027; doi:10.2337/diabetes.49.12.2021

  4. Yaney, G C

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  5. Yasuda, H

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

  6. Yokono, K

    • Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes December 2000 49:1998-2006; doi:10.2337/diabetes.49.12.1998

Z

  1. Zhou, Y

    • Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes December 2000 49:2012-2020; doi:10.2337/diabetes.49.12.2012

  2. Zisman, A

    • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes December 2000 49:2126-2134; doi:10.2337/diabetes.49.12.2126

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement